Endonovo Therapeutics (OTCQB: ENDV), an innovative biotechnology company, is poised to profit as the wearable medical devices market is forecasted to rapidly increase over the coming years. An article discussing the company reads, “The global wearable medical devices market is anticipated to grow to $66.8 billion by 2026, a Grandview Research report published in April 2019 suggests (http://nnw.fm/Z72qG). The market is forecast to expand at a CAGR of 26.1% over the period, with several factors contributing to the growth. . . . Increased health awareness and a better understanding of the need for constant monitoring will both help the market expand. In addition, the Western world’s population is aging, and the prevalence of chronic medical conditions is increasing. Wearable devices can be used to monitor various important health parameters, to prompt a more active lifestyle and even to address an array of treatable conditions.”
To view the full article, visit http://nnw.fm/F4ELr
About Endonovo Therapeutics Inc.
Endonovo Therapeutics is a commercial-stage developer of noninvasive wearable electroceuticals(TM) therapeutic devices. The company’s current portfolio of commercial and clinical-stage wearable electroceuticals therapeutic devices addresses wound healing, pain, postsurgical pain and edema, cardiovascular disease, chronic kidney disease and central nervous system (“CNS”) disorders including traumatic brain injury (“TBI”), acute concussions, postconcussion syndrome and multiple sclerosis. The company’s noninvasive electroceutical therapeutic device, SofPulse(R), using pulsed short-wave radiofrequency at 27.12 MHz, has been FDA cleared and CE marked for the palliative treatment of soft-tissue injuries and postoperative pain and edema, and has CMS national coverage for the treatment of chronic wounds. The company’s current portfolio of preclinical-stage electroceuticals therapeutic devices address chronic kidney disease, liver disease nonalcoholic steatohepatitis (“NASH”), cardiovascular and peripheral artery disease (“PAD”), and ischemic stroke. The company’s noninvasive, wearable electroceuticals therapeutic devices work by restoring key electrochemical processes that initiate anti-inflammatory and growth-factor cascades necessary for healing to occur. For more information, visit the company’s website at www.Endonovo.com.
NOTE TO INVESTORS: The latest news and updates relating to ENDV are available in the company’s newsroom at http://nnw.fm/ENDV
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.NetworkNewsWire.com